Anastasia Khvorova
Founder
Atalanta Therapeutics
Atalanta Therapeutics is developing di-siRNA technology to utilize RNA interference for gene silencing, targeting the underlying mechanisms of neurodegenerative diseases such as Huntington's disease. This approach aims to provide effective treatment options that address the urgent need for interventions in central nervous system disorders.
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$205MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Neil Aronin
Founder
Craig Mello
Founder
Product
Problem
Many neurodegenerative diseases affecting the central nervous system (CNS) lack effective treatments that address the underlying genetic causes. Traditional therapeutic approaches often fail to halt or reverse disease progression, leaving a significant unmet need for targeted interventions.
Solution
Atalanta Therapeutics is developing RNA interference (RNAi) therapeutics utilizing its di-siRNA platform to silence genes implicated in neurodegenerative disorders. The company's approach aims to halt disease progression by directly targeting the messenger RNA (mRNA) of disease-causing genes, preventing the production of harmful proteins. Atalanta's di-siRNA technology is designed to enhance the delivery of RNAi therapeutics across the blood-brain barrier, enabling effective gene silencing within the CNS. This strategy offers the potential to treat a range of neurological conditions, including Huntington's disease and KCNT1-related epilepsy, by addressing the root cause of these disorders.
Target Audience
The primary target audience includes patients suffering from neurodegenerative diseases, their families, and pharmaceutical companies seeking novel therapeutic approaches for CNS disorders.
Features
- di-siRNA technology platform for enhanced delivery of RNAi therapeutics to the CNS
- Targeted gene silencing to reduce the production of disease-causing proteins
- Development of therapies for Huntington's disease, KCNT1-related epilepsy and other neurodegenerative diseases
- Preclinical data demonstrating durable suppression of spontaneous seizures in a mouse model of KCNT1 genetic epilepsy
- Preclinical data demonstrating widespread and durable knockdown of HTT in non-human primate brain